ICU Medical (NASDAQ:ICUI) Stock Rating Upgraded by StockNews.com

ICU Medical (NASDAQ:ICUI) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.

Several other research analysts also recently weighed in on the company. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Wednesday, December 11th. Raymond James set a $97.00 price objective on shares of ICU Medical in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, ICU Medical presently has a consensus rating of “Buy” and a consensus price target of $168.67.

ICU Medical Stock Down 1.6 %

ICUI opened at $139.32 on Friday. The company has a fifty day moving average of $151.64 and a two-hundred day moving average of $162.55. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of -30.49 and a beta of 0.73. ICU Medical has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of ICU Medical by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after purchasing an additional 17,805 shares during the last quarter. State Street Corp increased its position in shares of ICU Medical by 9.3% during the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after acquiring an additional 77,506 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of ICU Medical by 7.4% in the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock valued at $109,920,000 after acquiring an additional 49,108 shares during the period. Geode Capital Management LLC lifted its holdings in shares of ICU Medical by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after acquiring an additional 48,106 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of ICU Medical by 18.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock worth $83,788,000 after purchasing an additional 82,982 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.